Accès ouvert déclaré 2022 article

Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey

Yusuf Önlen, Tayibe Bal, Mehmet Çabalak, Nefise Çuvalcı Öztoprak, Nagehan Didem Sarı, Behice Kurtaran, Ebubekir Şenateş, Alper Gündüz, Esra Yerlikaya Zerdali, Hasan Karsen, Ayşe Alga Batırel, Rıdvan Karaali, Rahmet Güner, Tansu Yamazhan, Şükran Köse, Nurettin Erben, Nevin İnce, İftihar Köksal, Figen Sarıgül Yıldırım, Gülşen Yörük, Süheyla Kömür, Sibel Yıldız Kaya, Şaban Esen, Özgür Günal, İlknur Esen Yıldız, Dilara İnan, Şener Barut, Mustafa Namıduru, Selma Yegane Tosun, Kamuran Türker, Alper Şener, Kenan Hızel, Nurcan Baykam, Fazılet Duygu, Esragül Akıncı, Güray Can, Ülkü User, Hanefi Cem Gül, Ayhan Akbulut, Güven Çelebi, Mahmut Sünnetçioğlu, Oğuz Karabay, Hayat Kumbasar Karaosmanoğlu, Fatma Sırmatel, Fehmı Tabak

4Citations signalées, ce qui n’est pas une note de qualité

37Institutions déclarées

1Pays d’affiliation déclarés

Rattachement africain : tr. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: The number and proportion of elderly patients living with chronic hepatitis C are expected to increase in the coming years. We aimed to compare the real-world efficacy and safety of direct-acting antiviral treatment in elderly and younger Turkish adults infected with chronic hepatitis C. METHODS: In this multicenter prospective study, 2629 eligible chronic hepatitis C patients treated with direct-acting antivirals between April 2017 and December 2019 from 37 Turkish referral centers were divided into 2 age groups: elderly (≥65 years) and younger adults (<65 years) and their safety was compared between 2 groups in evaluable population. Then, by matching the 2 age groups for demographics and pretreatment risk factors for a non-sustained virological response, a total of 1516 patients (758 in each group) and 1244 patients (622 in each group) from the modified evaluable population and per-protocol population were included in the efficacy analysis and the efficacy was compared between age groups. RESULTS: The sustained virological response in the chronic hepatitis C patients was not affected by the age and the presence of cirrhosis both in the modified evaluable population and per-protocol population (P = .879, P = .508 for modified evaluable population and P = .058, P = .788 for per-protocol population, respectively). The results of the per-protocol analysis revealed that male gender, patients who had a prior history of hepatocellular carcinoma, patients infected with non-genotype 1 hepatitis C virus, and patients treated with sofosbuvir+ribavirin had a significantly lower sustained virological response 12 rates (P < .001, P = .047, P = .013, and P = .025, respectively). CONCLUSION: Direct-acting antivirals can be safely used to treat Turkish elderly chronic hepatitis C patients with similar favorable efficacy and safety as that in younger adults.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey
Date Crossref: 15/10/2022
Éditeur: AVES YAYINCILIK A.Ş.
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

Mustafa Kemal University pays non établi dans la notice
Université ou école supérieure
Antalya Eğitim ve Araştırma Hastanesi pays non établi dans la notice
Établissement de santé
Cukurova University Department of Infectious Diseases and Clinical Microbiology pays non établi dans la notice
Université ou école supérieure
Istanbul Medeniyet University pays non établi dans la notice
Université ou école supérieure
Şişli Etfal Eğitim ve Araştırma Hastanesi pays non établi dans la notice
Établissement de santé
Haseki Eğitim ve Araştırma Hastanesi pays non établi dans la notice
Établissement de santé
Harran University Department of Infectious Diseases and Clinical Microbiology pays non établi dans la notice
Université ou école supérieure
Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi pays non établi dans la notice
Établissement de santé
Kartal Koşuyolu High Specialization Training and Research Hospital pays non établi dans la notice
Établissement de santé
Tekirdağ Namık Kemal University Department of Infectious Diseases and Clinical Microbiology pays non établi dans la notice
Université ou école supérieure
Memorial Ankara Hospital pays non établi dans la notice
Établissement de santé
Ege University Department of Infectious Diseases and Clinical Microbiology pays non établi dans la notice
Université ou école supérieure

Mustafa Kemal University, Antalya Eğitim ve Araştırma Hastanesi et Department of Infectious Diseases and Clinical Microbiology — Cukurova University, avec 9 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Hepatitis C virus researchHepatitis B Virus StudiesHepatitis Viruses Studies and Epidemiology

Lire en accès ouvert Consulter la publication primaire Ouvrir le DOI